Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 22, 2014

View Archived Issues

Novel pan tyrosine kinase receptor inhibitor identified for the treatment of cancer

RXi Pharmaceuticals updates on phase II program of RXI-109 in scar recurrence prevention

Report of phase I evaluation of a STAT3 ASO for hepatocellular carcinoma

Takeda describes PDE10A inhibitor TAK-063

Phase I study initiated for ProMetic IV plasminogen

SOV Therapeutics' oral testosterone undecanoate meets phase IIb study endpoints

Pfizer starts phase II trial of anti-myostatin antibody in DMD

Further phase III data reveal efficacy of LCZ-696 in hypertension and heart failure

Bayer presents novel TTK inhibitors for cancer

NESP approved for anemia with myelodysplastic syndromes in Japan

Kyowa Hakko Kirin receives additional indication approval for Poteligeo in Japan

Prima BioMed completes acquisition of Immutep

Kadcyla fails to show superiority to Herceptin plus taxane therapy in untreated breast cancer

Polaris' ADI-PEG20 receives E.U. orphan drug status for MPM

Researchers report phase I results on taselisib in breast cancer

Medeia Therapeutics discloses new cytoprotectants

Johns Hopkins University patents novel aptamers for sickle cell anemia

HCV treatment designed by French and U.S. organizations

European orphan drug designation for Halozyme's PEGPH-20 in pancreatic cancer

FDA approves Lynparza, and companion diagnostic, for germline BRCA-mutated advanced ovarian cancer

EMA committee recommends approval of Xadago to treat mid- to late-stage Parkinson's disease

CHMP backs approval of Orexigen's naltrexone/bupropion for weight management

U.S. approval for Cubist's ceftolozane/tazobactam for cUTI and cIAI

FDA approves Rapivab for acute uncomplicated influenza

Intravenous administration of Erwinaze obtains U.S. approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...